A detailed history of Walleye Capital LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 174,581 shares of ATXS stock, worth $1.64 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
174,581
Previous 2,500 6883.24%
Holding current value
$1.64 Million
Previous $22,000 8636.36%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.97 - $12.65 $618,382 - $872,078
68,939 Added 65.26%
174,581 $1.92 Million
Q2 2024

Aug 14, 2024

BUY
$8.83 - $13.51 $818,532 - $1.25 Million
92,699 Added 716.21%
105,642 $961,000
Q1 2024

May 15, 2024

BUY
$6.99 - $16.69 $90,471 - $216,018
12,943 New
12,943 $182,000
Q3 2023

Nov 14, 2023

BUY
$6.89 - $9.86 $134,561 - $192,565
19,530 New
19,530 $145,000

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $143M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.